Function (short‐term) WOMAC scale from: 0 to 100 (higher is worse function). · patients with hip osteoarthritis
1 finding from 1 review
Migraine frequency Number of attacks · patients with Raynaud's phenomenon
1 finding from 1 review
Duration of attacks · patients with Raynaud's phenomenon
1 finding from 1 review
Severity of attacks · patients with Raynaud's phenomenon
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · patients with Raynaud's phenomenon
1 finding from 1 review
Patient global Disability due to Raynaud's assessed on a 10‐cm visual analogue scale (0 = no disability, 10 = maximal disability) · patients with Raynaud's phenomenon
1 finding from 1 review
Withdrawals due to adverse events · patients with Raynaud's phenomenon
Calcium channel blockers showed no clear difference in number of withdrawals due to adverse events Number of participants… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events Number of participants who died or withdrew and were hospitalized as a result of adverse effects of treatment · patients with Raynaud's phenomenon
1 finding from 1 review
Number of participants with change in bone pain (disappearance of pain)¹assessed on VAS · Paget's disease of bone
Bisphosphonates probably leads to higher number of participants with change in bone pain (disappearance of… compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants who needed orthopaedic surgery (not measured) · Paget's disease of bone
1 finding from 1 review
Number of participants with change in quality of life measures (not measured) · Paget's disease of bone
1 finding from 1 review
Number of participants with change in hearing thresholds (not measured) · Paget's disease of bone
1 finding from 1 review
Number of participants who experienced side effects related to use of bisphosphonates · Paget's disease of bone
Zoledronate showed no clear difference in number of participants who experienced side effects related to use… compared with pamidronate or risedronate (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Paget's disease of bone
It is very uncertain whether zoledronate changes number of participants who withdrew due to adverse events… compared with pamidronate or risedronate (very low certainty).
1 finding from 1 review
Number of participants who experienced radiologically‐confirmed fractures · Paget's disease of bone
It is very uncertain whether bisphosphonates changes number of participants who experienced radiologically‐confirmed… compared with placebo (very low certainty).
1 finding from 1 review
Number of participants who needed orthopaedic surgery (not measured) · Paget's disease of bone
1 finding from 1 review
Number of participants with change in quality of life measures (not measured) · Paget's disease of bone
1 finding from 1 review
Number of participants with change in hearing thresholds (not measured) · Paget's disease of bone
1 finding from 1 review
Number of participants who experienced side effects related to use of bisphosphonates · Paget's disease of bone
Bisphosphonates showed no clear difference in number of participants who experienced side effects related to use… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Paget's disease of bone
Bisphosphonates showed no clear difference in number of participants who withdrew due to adverse events compared with placebo (low certainty).
1 finding from 1 review